BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
The project is a collaboration between IIT Delhi and AIIMS
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
Subscribe To Our Newsletter & Stay Updated
